GIROLAMI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.530
AS - Asia 2.465
EU - Europa 2.144
AF - Africa 17
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 12
SA - Sud America 3
Totale 24.185
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.514
CN - Cina 1.096
SG - Singapore 812
FI - Finlandia 499
VN - Vietnam 482
SE - Svezia 397
DE - Germania 342
FR - Francia 268
UA - Ucraina 179
IT - Italia 173
GB - Regno Unito 172
HK - Hong Kong 30
IE - Irlanda 30
IN - India 27
NL - Olanda 22
RU - Federazione Russa 21
CA - Canada 14
CZ - Repubblica Ceca 10
EU - Europa 10
AU - Australia 9
MA - Marocco 7
BG - Bulgaria 5
NZ - Nuova Zelanda 5
CH - Svizzera 4
ET - Etiopia 4
LY - Libia 4
TR - Turchia 4
BE - Belgio 3
BR - Brasile 3
ES - Italia 3
IR - Iran 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
JP - Giappone 2
NO - Norvegia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
DK - Danimarca 1
EE - Estonia 1
HU - Ungheria 1
IQ - Iraq 1
KG - Kirghizistan 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LT - Lituania 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
PA - Panama 1
PH - Filippine 1
PL - Polonia 1
PT - Portogallo 1
RS - Serbia 1
UZ - Uzbekistan 1
Totale 24.185
Salva come PNG Salva come JPEG
Città #
Fairfield 3.199
Woodbridge 1.941
Houston 1.595
Chandler 1.560
Ashburn 1.328
Wilmington 1.172
Seattle 1.144
Ann Arbor 1.137
Cambridge 1.085
Jacksonville 991
Singapore 633
Princeton 541
Boardman 511
Dong Ket 480
San Diego 323
Beijing 276
Santa Clara 262
Roxbury 224
Medford 210
Nanjing 209
Des Moines 173
Helsinki 173
Hebei 65
Norwalk 62
Padova 62
Shenyang 61
Nanchang 60
Jiaxing 50
London 47
Changsha 43
Tianjin 42
Redwood City 32
Dublin 30
Hong Kong 30
Guangzhou 28
Jinan 27
New York 27
Kilburn 18
Washington 16
Ogden 14
Indiana 12
Borås 11
Detroit 11
Dallas 9
Hefei 9
Rockville 9
Tappahannock 9
Zhengzhou 9
Chicago 7
Chiswick 7
Falls Church 7
Hangzhou 7
Mestre 7
Rome 7
Shanghai 7
Brno 6
Los Angeles 6
Ningbo 6
Nürnberg 6
Southwark 6
Taizhou 6
Wandsworth 6
Amsterdam 5
Milan 5
Muenster 5
Phoenix 5
Prescot 5
Sofia 5
Yuncheng 5
Addis Ababa 4
Chengdu 4
Fuzhou 4
Kharkiv 4
Kunming 4
Lanzhou 4
Munich 4
Nutley 4
Rabat 4
San Francisco 4
Taiyuan 4
Treviso 4
Tripoli 4
Acton 3
Auckland 3
Civitanova Marche 3
Fremont 3
Haikou 3
Hounslow 3
Madrid 3
Mainz 3
Mogliano Veneto 3
Olomouc 3
Orange 3
Plaidt 3
Pune 3
Salé 3
Venice 3
Wuhan 3
Yellow Springs 3
Yenibosna 3
Totale 20.192
Salva come PNG Salva come JPEG
Nome #
1-Desamino-8-D-arginine vasopressin (DDAVP) infusion in type IIB von Willebrand's disease: shortening of bleeding time and induction of a variable pseudothrombocytopenia. 190
Abnormal propeptide processing resulting in the presence of two abnormal species of protein C in plasma - Characterization of the dysfunctional protein C Padua(3) (Protein CR-1L/propeptide) 141
Activated protein C resistance in normal and pre-eclamptic pregnancies 139
Type IIB von Willebrand Factor induces phospholipase A2 activation and cytosolic Ca2+ increase in platelets 129
Venous thrombosis in von Willebrand disease as observed in one centre and as reported in the literature. 128
FACTOR-VIII VONWILLEBRAND-FACTOR ABNORMALITIES DURING L-ASPARAGINASE TREATMENT IN PATIENTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA 123
Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. 122
Arg 304 Gln (FVII Padua) and Ala 294 Val mutations are equally present in patients with FVII deficiency and thrombosis. 120
Spontaneous hemarthrosis in combined Glanzmann thrombasthenia and type 2N von Willebrand disease. 119
Aspirin and bleeding time 116
Platelet serotonin and platelet aggregation in the differential diagnosis of thrombocytosis 115
Selection of both normal and bleeding patients is indicated before desmopressin administration 115
Abnormally large von Willebrand factor multimers in Henoch-Schönlein purpura. 113
Bernard-Soulier Syndrome: diagnosis by ELISA method using monoclonal antibodies in 2 new unrelated patients 112
Activated FVII levels in factor VII Padua (Arg304Gln) coagulation disorder and in true factor VII deficiency: a study in homozygotes and heterozygotes 112
Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP. 112
Multiple, relapsing thrombosis in a young man with primary thrombocytosis 110
Pregnancy and oral contraceptives in congenital bleeding disorders of the vitamin K-dependent coagulation factors. 110
Heparin induced thrombocytopenia: Prevalence in a large cohort of patients and confirmed role of PF4/heparin complex as the main antigen for antibodies 108
Associated risk factors and arterial occlusions in patients with von Willebrand disease: Analysis of the literature and report of two cases 108
Myocardial infarction in two cousins heterozygous for ASN41HIS autosomal dominant variant of Bernard-Soulier syndrome. 107
The significance of plasma and /or platelet activated products after apheresis procedures 107
The biological inertia of coumarin-induced pre-factors (so called PIVKAs) 106
A forgotten or minimized head trauma, rather than a mild FVII deficiency, is the most likely cause of a subdural hematoma 106
A novel type I factor X variant (factor X Cys350Phe) due to loss of a disulfide bond in the catalytic domain 105
Plasma and platelet beta-thromboglobulin levels in patients with May-Hegglin anomaly 105
Spectrum of 5’UTR mutations in ANKRD26 gene in patients with inherited thrombocytopenia: c.-140C>G mutation is more frequent than expected 104
Conformation sensitive gel electrophoresis for detection of factor X gene mutations 103
"Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. 103
Plasma fibrinolytic capacity in renal transplant recipients: Effect of steroid-free immunosuppression therapy. 103
The significance of thrombocytosis in old age 102
Acquired factor VIII:C inhibitor in a patient with Sjögren's syndrome: successful treatment with steroid and immunosuppressive therapy. 102
Normal and low molecular weight heparins: interaction with human platelets 102
Thrombotic manifestations in plasminogen deficiency and in plasminogen abnormalities. 102
A new ELISA method for the detection of serum bindable anti-platelet antibodies (SPBIG). 102
Heterozygous FXII deficiency is not associated with an increased incidence of thrombotic events: Results of a long term study 102
The Dysprothrombinemias due to Arg596 Mutations: A Conundrum With No Bleeding Tendency and Venous Thrombosis due to Antithrombin Resistance 102
Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. 100
Thrombosis-free surgical procedures in severe (Homozygote) factor XII deficiency: report of four additional cases and literature review 99
Heterozygous protein-S deficiency: a study of a large kindred. 99
Clinical and laboratory factors that affect the post-transfusion platelet increment 98
Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): a family study. 98
Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. 98
Naturally occurring Arg-1 to Leu mutation in human protein C (protein C Padua(3)) resulting in an abnormal propeptide processing and in a molecule with discrepant functional activities 98
Complex History of the Discovery and Characterization of Congenital Factor X Deficiency. 98
Familial thrombocythemia and/or thrombocytosis: apparently a rare disorder 97
Remission in hairy cell leukemia-variant following splenic radiotherapy alone 97
Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome 97
Pitfalls of protein C assays in patients with activated protein C resistance 96
A new global test for the evaluation of the protein C-protein S system. 96
Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family 95
Potentiation of anticoagulant response to warfarin by sulphinpyrazone: a double-blind study in patients with prosthetic heart valves. 95
Age as the major predictive factor of long-term response to splenectomy in immune thrombocytopenic purpura 95
MARKED BUT TRANSITORY ELEVATION OF HEPATIC TRANSAMINASES AFTER SUBCUTANEOUS CALCIUM HEPARIN ADMINISTRATION 94
Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. 94
The relationship between defective heparin cofactor activities and thrombotic phenomena in AT III abnormalities. 94
Normal pregnancy and delivery in essential thrombocythemia even without interferon therapy 93
Clinical significance of beta-thromboglobulin in patients with high platelet count 93
Childhood stroke associated with familial protein S deficiency. 93
FAILURE OF B-CELLS OF CHRONIC LYMPHOCYTIC-LEUKEMIA IN PRESENTING SOLUBLE AND ALLOANTIGENS 93
Diagnosis and follow-up of thrombotic thrombocytopenic purpura by means of von Willebrand factor collagen binding assay. 93
Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: Report of four cases and review of the literature 92
A highly polymorphic microsatellite in the factor V gene is an informative tool for the study of factor V-related disorders 92
Mild bleeding diathesis in a boy with combined severe haemophilia B (C(10400)-->T) and heterozygous factor V Leiden 92
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. 92
Inhibitory effect of prostacyclin and nitroprusside on type IIB von Willebrand factor-promoted platelet activation. 91
EDTA dependent pseudothrombocytopenia caused by antibodies against the cytoadhesive receptor of platelet gpIIB-IIIA. 91
Platelet aggregation induced by plasma from type IIB von Willebrand's disease patients is associated with an increase in cytosolic Ca2+ concentration. 91
Use of a radioimmunoassay for 5-hydroxytryptamine (5-HT) in thrombocytosis 91
Unexpected low prevalence of FVIII gene inversion in severe hemophilia A patients from north-eastern Italy 90
Thrombotic events in MYH9 gene-related autosomal macrothrombocytopenias (old May-Hegglin, Sebastian, Fechtner and Epstein syndromes). 90
Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends only on the lack of large multimers. 90
Thrombotic Events in Asymptomatic FXII Deficiency versus Symptomatic FXI Deficiency: Surprising Observations. 90
Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders 90
Vitamin K-Dependent Coagulation Factors That May be Responsible for Both Bleeding and Thrombosis (FII, FVII, and FIX) 89
A frequent factor XII gene mutation in Hageman trait. 88
Accuracy of two newly described D-dimer tests in patients with suspected deep venous thrombosis. 88
Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia 87
Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by haemodialysis 87
Partial gene deletion in a family with factor X deficiency. 87
Detection of B-cell monoclonality in fine needle aspiration by PCR analysis 87
Discrepancies between von Willebrand factor multimeric composition and other tests in some von Willebrand's disease variants. 86
The evaluation of factor VIII antigen by means of a simple slide test. 85
APC resistance, oral contraceptive therapy and deep vein thrombosis: settled and unsettled problems 85
Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor. 85
Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity? 85
Do hemophilia A and von Willebrand disease protect against carotid atherosclerosis? A comparative study between coagulopathics and normal subjects by means of carotid echo-color Doppler scan. 85
A NEW MUTATION (ARG 251TRP) IN THE CA2+ BINDING SITE OF FACTOR XPROTEASE DOMAIN APPEARS BE THE RESPONSIBLE FOR THE DEFECT IN THE EXTRINSIC PATHWAY ACTIVATION OF FACTORX PADUA. 85
Diagnosis of recurrent deep vein thrombosis. 84
Incidence of thrombocytosis in lymphomas 84
A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. 84
Discrepancies between clotting and amidolytic assay in congenital clotting disorders. 84
The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. 83
The effect of anticoagulant mixtures on BTG and PF4 levels. 83
Response to splenectomy in idiopathic thrombocytopenic purpura: prognostic value of the clinical and laboratory evaluation 83
A protein S functional assay yields unsatisfactory results in patients with activated protein C resistance. 83
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. 83
THE LONG TERM CLINICAL COURSE OF ACUTE DEEP VEIN THROMBOSIS OF THE ARM: PROSPECTIVE COHORT STUDY 82
The management of feto-maternal alloimmune thrombocytopenia: Report of three cases 82
Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors 82
Totale 9.896
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.237
article - articoli 88.237
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 176.474
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.899 0 0 0 0 0 0 459 595 702 543 327 273
2020/20213.183 197 245 125 279 108 194 73 309 443 217 373 620
2021/20224.267 69 486 433 366 130 301 209 513 200 75 506 979
2022/20233.103 691 289 107 332 548 405 4 190 346 16 133 42
2023/20241.238 67 191 167 105 90 91 72 54 41 13 162 185
2024/20252.047 17 468 326 244 873 118 1 0 0 0 0 0
Totale 24.326